



Review

Optimized Treatment of Nosocomial Peritonitis

Jan J. De Waele ^{1,2,*}, Federico Coccolini ³, Leonel Lagunes ^{4,5}, Emilio Maseda ^{6,7}, Stefano Rausei ⁸, Ines Rubio-Perez ^{9,10,11}, Maria Theodorakopoulou ¹² and Kostoula Arvaniti ¹³

- ¹ Department of Intensive Care Medicine, Ghent University Hospital, 9000 Ghent, Belgium
 - ² Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium
 - ³ General, Emergency and Trauma Surgery Department, Pisa University Hospital, 56124 Pisa, Italy; federico.coccolini@gmail.com
 - ⁴ Vall d'Hebron Institut de Recerca CRIPS, 08035 Barcelona, Spain; leonel.lagunes@uaslp.mx
 - ⁵ Facultad de Medicina, Universidad Autónoma de San Luis Potosí, 78210 San Luis Potosí, Mexico
 - ⁶ Department of Anesthesia and Critical Care, Hospital Quironsalud Valle del Henares, 28850 Madrid, Spain; emilio.maseda@gmail.com
 - ⁷ Department of Pharmacology and Toxicology, Complutense University of Madrid, 28040 Madrid, Spain
 - ⁸ General Surgery Unit, Department of Surgery, Cittiglio-Angera Hospital, ASST SetteLaghi, 21100 Varese, Italy; stefano.rausei@gmail.com
 - ⁹ Colorectal Surgery Unit, Department of General Surgery, Hospital Universitario La Paz, 28029 Madrid, Spain; i.rubio@acirujanos.es
 - ¹⁰ Hospital La Paz Institute for Health Research (Idipaz), 28029 Madrid, Spain
 - ¹¹ Universidad Autonoma de Madrid, 28029 Madrid, Spain
 - ¹² 1st Department of Critical Care Medicine & Pulmonary Services, School of Medicine, National and Kapodistrian University of Athens, Evangelismos Hospital, 10675 Athens, Greece; mariatheodor10@gmail.com
 - ¹³ Department of Intensive Care Medicine, Papageorgiou Hospital, 54646 Thessaloniki, Greece; arvanitik@hotmail.com
- * Correspondence: jan.dewaele@ugent.be; Tel.: +32-93-32-62-1; Fax: +32-93-32-49-95



Citation: De Waele, J.J.; Coccolini, F.; Lagunes, L.; Maseda, E.; Rausei, S.; Rubio-Perez, I.; Theodorakopoulou, M.; Arvaniti, K. Optimized Treatment of Nosocomial Peritonitis. *Antibiotics* **2023**, *12*, 1711. <https://doi.org/10.3390/antibiotics12121711>

Academic Editor: Vincent Jullien

Received: 5 October 2023

Revised: 24 November 2023

Accepted: 1 December 2023

Published: 8 December 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: This comprehensive review aims to provide a practical guide for intensivists, focusing on enhancing patient care associated with nosocomial peritonitis (NP). It explores the epidemiology, diagnosis, and management of NP, a significant contributor to the mortality of surgical patients worldwide. NP is, per definition, a hospital-acquired condition and a consequence of gastrointestinal surgery or a complication of other diseases. NP, one of the most prevalent causes of sepsis in surgical Intensive Care Units (ICUs), is often associated with multi-drug resistant (MDR) bacteria and high mortality rates. Early clinical suspicion and the utilization of various diagnostic tools like biomarkers and imaging are of great importance. Microbiology is often complex, with antimicrobial resistance escalating in many parts of the world. Fungal peritonitis and its risk factors, diagnostic hurdles, and effective management approaches are particularly relevant in patients with NP. Contemporary antimicrobial strategies for treating NP are discussed, including drug resistance challenges and empirical antibiotic regimens. The importance of source control in intra-abdominal infection management, including surgical and non-surgical interventions, is also emphasized. A deeper exploration into the role of open abdomen treatment as a potential option for selected patients is proposed, indicating an area for further investigation. This review underscores the need for more research to advance the best treatment strategies for NP.

Keywords: antibiotics; antimicrobials; sepsis; peritonitis; nosocomial infection; abdominal sepsis

1. Introduction

Despite advancements in diagnostic, surgical, and intensive care management, acute generalized peritonitis is a prevalent medical and surgical emergency that significantly contributes to non-trauma mortality worldwide [1].

Nosocomial peritonitis (NP) refers to peritonitis that is acquired in the hospital, most commonly after previous gastrointestinal surgery or as a complication of the treatment of another disease requiring hospital admission.

NP is a particular entity for a number of reasons. The epidemiological aspects are different from other forms of peritonitis: diagnosis is often challenging and the microbiology markedly variable, therefore requiring different empirical therapy compared to community acquired diseases.

In this narrative review, we aim to present an update on the various aspects of NP, describe a comprehensive approach, and provide intensivists a practical guide at the bedside for improvement of the overall management of patients with NP.

2. Epidemiology

Among the various types of intra-abdominal infections (IAI), primary, secondary, and tertiary peritonitis are recognized as distinct entities [2]. The term “primary peritonitis” refers to peritoneal inflammation and infection brought on by bacterial translocation, hematogenous dissemination, or iatrogenic contamination without macroscopically obvious damage to solid organs or viscera of the gastrointestinal or genitourinary tract. Secondary peritonitis is characterized as injury or perforation to a hollow viscus in the abdominal cavity that results in a direct contamination of the peritoneum; this lesion may be iatrogenic or spontaneous. Tertiary peritonitis is the progression of secondary peritonitis following treatment failure and is therefore a nosocomial infection per definition.

The primary focus of this review is NP, which is one of the most prevalent causes of sepsis and septic shock in the intensive care unit (ICU). The ABSES study found that roughly two thirds of abdominal infections in the ICU are nosocomial; among nosocomial infections, the authors distinguished early onset from late onset (below or beyond 7 days of hospital admission, respectively) with the latter being the most frequent (43%) [3]. NP commonly originates—in descending order of frequency—from the colon, appendix, stomach, small intestine, and biliary tract [4]. Risk factors for developing septic shock from secondary peritonitis include age >65 years, two or more bacteria found in the peritoneal fluid, and anaerobic bacteria in the peritoneal fluid [5].

NP, like every hospital-acquired infection, is frequently associated with multi-drug resistant (MDR) bacteria, such as MDR *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, or carbapenemase-producing Enterobacterales, which has, also, been linked to poor outcomes [6]. Immunocompromised patients, as well as patients under corticosteroid therapy, with a history of recent broad-spectrum antibiotics exposure, chronic lung or liver disease, and those hospitalized for more than 5 days are at significantly greater risk of MDR peritonitis [6].

The mortality of postoperative peritonitis is high [6]. In one of the largest studies on the subject to date, the ABSES study found mortality rates of up to 50% in subgroups of critically ill patients with IAI [3]. Well-established risk factors for poor prognosis include delayed intervention, i.e., after 24 h, which has been described as a prominent factor in treatment failure [3]. Other negative prognostic factors include high clinical severity scores (APACHE II ≥ 15 and SOFA >2), advanced age and male sex, involvement of >2 abdominal quadrants, poor nutritional status, low serum albumin, and history of cancer. In the same study, the setting and timing of infection acquisition, the severity of illness, and the intraperitoneal extent of infection were the main determinants of mortality, with outcomes consistently worse in patients with late-onset nosocomial abdominal infections.

3. Diagnosis and Clinical Approach

The most common cause of NP is postoperative complications, usually due to anastomotic leak, ischemia, or iatrogenic perforation. These can lead to sepsis with high morbidity and mortality [3], which emphasizes the need for prompt diagnosis with a low threshold for diagnostic investigations, including advanced imaging. These patients usually require ICU

with continuous monitoring and management of the clinical course and a multidisciplinary approach with close involvement of the surgical team.

A key element to diagnosis is early clinical suspicion when a patient deviates from a standard postoperative course, presents abnormal vital signs, signs of sepsis, abnormal biochemistry (including elevated inflammatory markers), or abdominal complications such as ileus, vomiting, or constipation. Clinical presentation may be atypical or masked, with unspecific or colicky abdominal pain that can be difficult to evaluate or attribute to a recent intervention [7]. When the pain is localized, the presence of surgical wounds or drains may cause confusion. Evaluation of the drain effluent, if present and abnormal, either macroscopically or based on lab results, can be helpful in diagnosing postoperative complications; however, a normal drain effluent does not rule out peritonitis. Moreover, in sedated mechanically ventilated patients in the ICU, clinical signs and clinical examination of the abdomen may be unspecific and not reliable [8].

Inflammatory markers can aid the postoperative diagnosis of peritonitis, especially if there is a progressive increase compared to baseline; yet, they are not specific, particularly in the critically ill patients. Although white blood cell count has been extensively studied and used in clinical practice, it is a weak and non-specific marker of postoperative peritonitis. Other biomarkers have been used as tools to rule out postoperative peritonitis. C-reactive protein (CRP) can be significantly elevated in patients presenting an anastomotic leak following colorectal surgery and is particularly useful because of the reported negative predictive value of up to 99% [9]. Similarly, procalcitonin has also been evaluated as a negative predictor of anastomotic leak in colorectal surgery [10]. Most biomarkers perform better when analyzed a few days after surgery; still, it is more appropriate to consider trends in biomarkers rather than absolute values.

Contrast-enhanced (with intravenous media) Computed Tomography (CT) is the most informative and commonly used technique in the diagnosis of NP. The addition of oral (or enteral/rectal) contrast media reduces the number of false negative results and improves sensitivity when it reaches the anastomosis [11]. In critically ill patients in whom CT cannot be performed, bedside ultrasound can serve as an easily accessible tool and aid diagnosis, despite its low sensitivity. If there is high suspicion or the patient is already septic, further investigations should not delay surgery. Early reintervention has been demonstrated to improve outcomes [12].

4. Microbiology

NP is caused by a wide range of microorganisms that include aerobic and anaerobic Gram-negative and Gram-positive bacteria. Among Gram-negative bacteria, Enterobacteriales are the most prevalent microorganisms, while streptococci and enterococci are the most frequently isolated Gram-positive bacteria [13,14]. *Staphylococcus aureus*, non-fermenting Gram-negative bacteria such as *Pseudomonas aeruginosa* and *Acinetobacter baumannii*, and *Candida* species are implicated in NP in selected patient populations [15–19]. NP is generally considered as a polymicrobial infection [6,20,21]. The isolated microorganisms are typically a mixture of aerobic and anaerobic Gram-negative and Gram-positive bacteria depending on specific risk factors such as the site of perforation, previous antibiotic exposure, and comorbidities [6,14]. Gram-negative aerobic and anaerobic bacteria are principally implicated in gastroduodenal perforation and most importantly in intestinal/colonic-related peritonitis, while Gram-positive bacteria account for about 30–40% of the isolates, regardless of the site of perforation [6,14]. Enterococci have been isolated in about 30–40% in NP cases, with existing evidence of significant pathogenicity for specific patient populations, such as elderly patients with severe IAI who are frequently postoperative [15,22–24].

In the last three decades, antimicrobial resistance in NP has emerged as a serious global threat alongside other nosocomial infections in critically ill patients. In hospitals and countries where MDR pathogens are endemic, NP frequently involves MDR microorganisms [24–28], carbapenem resistance, and extended-spectrum β -lactamase (ESBL) production in Gram-negative bacteria, especially in *Klebsiella pneumoniae*, *Acinetobacter bau-*

mannii, and *Pseudomonas aeruginosa*; to a lesser extent, vancomycin resistance in *Enterococcus faecium* and methicillin-resistance in *Staphylococcus aureus* have been repeatedly reported for bacterial strains isolated in NP cases from critically ill patients [29,30].

In a recent multicenter epidemiological study on IAIs in ICU patients, 68% of all cases were hospital-acquired and Gram-negatives were the most common pathogens with Enterobacterales at 64% and *E. coli* at 45% [3]. Gram-positive aerobic bacteria were isolated in 49% of the patients; enterococci were the most frequently isolated Gram-positive bacteria (32%), and anaerobic bacteria and fungi were isolated in 14% and 16% of the patients, respectively. Antimicrobial resistance was common and reached 26.3%, without significant variations between community- and healthcare-acquired IAI. Carbapenem resistance reached 15.9% in Eastern and South-Eastern Europe. For *Pseudomonas aeruginosa*, even though less frequently isolated, resistance against all antibiotic classes was above 20% in most European countries. VRE prevalence was above 15% without important geographic variations [3].

5. Fungal Infections

Fungal peritonitis is a rare but serious complication with high mortality, especially in critically ill patients. The most common risk factor for acute fungal peritonitis is recent abdominal surgery involving the gut [31]. Some other factors have been identified such as long-term peritoneal dialysis, immunosuppression, and prior antibiotic exposure [32,33].

Candida spp. has been the most widely reported microorganism involved, although some reports of *Aspergillus* spp. and *Zygomycetes* spp. have been described; these, however, are very rarely involved in community-acquired IAIs. There is a high variety of epidemiological and demographic conditions according to geographic location, and this has been changing in recent years. *C. albicans* remains the dominant species in Europe followed by *C. glabrata* and *C. parapsilosis*, whereas in Latin America *C. albicans* and *C. parapsilosis* predominate. In the USA, a higher proportion of non-albican cases account for more than 50% [34]. Recent *C. auris* outbreaks in different parts of the world have gained attention, resulting in high mortality rates due, among other reasons, to fluctuating susceptibility for available antifungals.

The reported high mortality of fungal IAIs is partly related to diagnostic difficulties; differentiation between contamination and infection when *Candida* spp. is recovered from intra-abdominal samples is currently debatable. Even so, fungal NP has been associated with poor prognosis [31,33]. The diagnostic value of blood cultures in this setting is limited. Various clinical scores with high negative predictive value have been used to rule out fungal peritonitis in the initial diagnostic approach [35]. Non-culture-based methods, such as Mannan antigen and anti-mannan antibodies, specific polymerase chain reaction (PCR) for *Candida* spp., and the detection of Candida Germ Tube Antibodies (CAGTA), have been investigated. They all have limitations for routine clinical use due to a lack of official standardization, important financial cost, and increased workload for the laboratory. 1,3- β -D-glucan (a component of the inner layer of the fungal wall) has been reported as a highly promising biomarker for fungal peritonitis. All these non-culture diagnostic tests are of great usefulness for epidemiological investigation and when screening populations to diagnose or to stop prophylactic antifungal treatment; however, who should be tested with which test to obtain the higher cost-benefit relation still remains a subject for further study [36].

The treatment of fungal peritonitis requires prompt and aggressive management as a delay in therapy can lead to increased morbidity and mortality. Due to difficulties in diagnosing fungal IAIs, prophylaxis, empirical, preemptive, and directed therapy strategies have been proposed (Figure 1). Empirical therapy refers to patients with suspicion, risk factors, and clinical signs of infection not explained by any other known or evident cause and in the absence of another causative pathogen. Preemptive therapy refers to the use of antifungals for a step further than suspicion with all the above plus a positive biomarker. Neither fluconazole nor caspofungin has been shown to reduce significantly in-

vasive candidiasis-related mortality in critical care settings when prescribed as prophylaxis or empirical therapy [37–40]. Current guidelines and expert task forces recommend an echinocandin as an initial or empirical treatment rather than fluconazole based on decreased susceptibility of fungi to azoles worldwide and especially in critically ill patients [35,41,42]. An aggressive strategy for empirical coverage of fungal agents needs to be followed by appropriate de-escalation policy whenever possible [43].




Figure 1. Proposed approach to intra-abdominal candidiasis.

Prompt adequate abdominal source control has been identified as the most important risk factor for improved survival in these patients [44]. It is imperative that drainage of infected fluid collections, debridement of infected tissues, removal of devices or foreign bodies, and definitive measures to correct anatomic derangements that result in ongoing microbial contamination and to restore optimal function must be pursued as soon as possible.

Therefore, a combination of careful risk assessment, fungal biomarkers, and microbiological investigation of infection site samples should guide the initiation and continuation or discontinuation of early antifungal therapy in critically ill patients.

6. Current Strategies in the Antibiotic Treatment of Nosocomial Peritonitis

Early source control and appropriate antibiotic therapy are the cornerstones in the management of complicated IAI (cIAI). As described above, cIAIs are usually polymicrobial in nature and are caused by a wide variety of microorganisms [2]. Current guidelines suggest that empirical antibiotics for cIAIs should be active against Enterobacterales, anaerobes, and enteric Gram-positive streptococci and should be driven by disease severity and reports on local MDR epidemiological data (at the ICU, region, or country level).

Table 1 summarizes the suggested regimens of recent clinical guidelines regarding the treatment of nosocomial IAIs [45–49]. The optimal choice of empirical antibiotics for cIAIs may be difficult and challenging due to the diverse pathogens and the likelihood of infection caused by MDR pathogens. The increasing rate of ESBL-producing and carbapenem-resistant Enterobacterales observed in community-acquired infections, alongside the complexity of the pathogens of NP (difficult-to-treat *Pseudomonas aeruginosa*, carbapenem-resistant *Acinetobacter baumannii*, *Enterococcus* spp., *Candida* spp.), represent a major challenge in the treatment of IAI [3,50]. Moreover, important diversity in therapeutic regimens is observed between geographical regions and hospital settings. As in other infectious diseases, inappropriate antibiotic treatment or delayed therapy for cIAIs is associated with therapeutic failure and increased mortality [51,52].

Table 1. Suggested regimens for empirical treatment of healthcare-associated / nosocomial IAIs.

Author	Year	Mild to Moderate	Severe	Ref.
Spanish consensus	2009	Piperacillin/tazobactam ± Fluconazole For β-lactam allergic patients: Tigecycline ± Fluconazole		[47]
SIS/IDSA	2010	Meropenem or Imipenem or Doripenem or Piperacillin/tazobactam or Ceftazidime or (Cefepime + Metronidazole) or Aminoglycosides or Colistin		[44]
WSES	2013	Piperacillin/tazobactam + Tigecycline + Fluconazole	Piperacillin/tazobactam + Tigecycline + Echinocandin Alternative: Meropenem or Imipenem or Doripenem + Teicoplanin + Echinocandin	[46]
Asian consensus	2014	Meropenem or Imipenem or Doripenem or Piperacillin/tazobactam Alternative: Cefepime or (Levofloxacin or Ciprofloxacin + Metronidazole) For β-lactam allergic patients: Tigecycline or Moxifloxacin or Ertapenem	Meropenem or Imipenem or Doripenem Alternative: Meropenem or Imipenem or Doripenem + Vancomycin or Linezolid OR Tigecycline + Aztreonam or Ciprofloxacin or Levofloxacin For β-lactam allergic patients: Tigecycline + (Ciprofloxacin or Levofloxacin) Or Carbapenem or Tigecycline or (Polymixin B or Colistin ± Aminoglycoside) Or Carbapenem + Tigecycline or Polymixin B or Colistin	[48]
SFAR	2015	Piperacillin/tazobactam ± Amikacin Alternative: (Imipenem or Meropenem) ± Amikacin For β-lactam allergic patients: Ciprofloxacin + Amikacin + Vancomycin + Metronidazole Or Aztreonam + Amikacin + Vancomycin + Metronidazole Or Tigecycline + Ciprofloxacin		[45]

A common treatment regimen for NP is the combination of β-lactams with β-lactamase inhibitors, such as piperacillin/tazobactam, for its activity in vitro against *Pseudomonas aeruginosa* and ESBL-producing or AmpC-producing Enterobacterales. However, in the MERINO trial, in patients with *Escherichia coli* or *Klebsiella pneumoniae* infection and ceftriaxone resistance among the implicated pathogens, definitive treatment with piperacillin-tazobactam compared with meropenem did not result in a noninferior 30-day mortality [53]. In the MERINO-2 trial, in patients with bloodstream infection due to AmpC-producing Enterobacterales, piperacillin-tazobactam had microbiological failures [54]. Non-ESBL-producing strains showed resistance rates to piperacillin/tazobactam (according to EUCAST cut-off points) of 27.4% for *Escherichia coli* and 38.1% for *Klebsiella pneumoniae* [55]. For decades, carbapenems have been positioned as the antibiotics of choice in the empirical treatment of infections caused by MDR pathogens (Table 1) [48,56], being the empirical choice when an infection caused by ESBL-producing or AmpC-producing Enterobac-

terales is suspected [57,58]. These data were supported by susceptibility studies that questioned the value of penicillin/ β -lactam inhibitor combinations (amoxicillin/clavulanic acid, piperacillin/tazobactam) and quinolones [59]. Yet, firm conclusions on the use of piperacillin/tazobactam specifically in NP cannot be reached. Moreover, the use of piperacillin/tazobactam instead of meropenem and vice versa largely depends on the prevalence of ESBL-producing and carbapenem-resistant Enterobacterales in each ICU. Over time, the increased use of carbapenems led to the emergence of carbapenemase-producing Enterobacterales (CPE). Concomitantly, *Pseudomonas aeruginosa* (one of the most frequent pathogen in IAIs) and *Acinetobacter baumannii* have shown a marked decrease in susceptibility to carbapenems in NP isolates [50,60,61]. Tigecycline (in high doses) has been included in the proposed combined antibiotic regimens for the treatment of NP in severe patients, with favorable clinical results [62], but its use in critically ill patients should be carefully considered. Combined antibiotic treatment regimens that include tigecycline are an alternative to carbapenems as monotherapy, not only because of their extended spectrum of activity, but also as carbapenem-sparing combinations aimed at possible future improvement or restoration of the activity of carbapenems. Furthermore, tigecycline has activity against MDR Gram-positive organisms and anaerobes.

A retrospective study showed that two groups of species, namely Enterococcus (29%) and Candida (33%), were more common in NP than in community-acquired IAIs, and 9% of *Enterococcus* isolates were resistant to vancomycin [63]. IAI treatment guidelines agree on the use of antimicrobials that cover enterococci in NP [25]. Vancomycin shows activity against enterococci and MRSA; however, the tolerance of these microorganisms to the antibiotic must be taken into consideration under specific circumstances [64]. In the case of MRSA, the tolerance and heteroresistance of certain strains to vancomycin may have clinical implications in infections in critically ill patients. Although the presence of MRSA strains with vancomycin resistance does not seem to be a serious clinical problem for the time being, vancomycin-resistant *Enterococcus faecium* (VRE) has been reported as an increasing problem in many countries [65]. These facts compromise the efficacy of vancomycin and makes it necessary to consider alternate antibiotics with activity against Gram-positive bacteria such as daptomycin or linezolid, as recommended by clinical guidelines (Table 1). MDR Gram-positive coverage is suggested for patients with risk factors for MDR pathogens and clinical severity necessitating a broad empirical antibiotic regimen awaiting the culture results. More specifically, for critically ill ICU patients with NP, combination regimens to cover both Gram-negative and Gram-positive MDR pathogens may be indicated depending on the local ecology [45–49,66,67].

New β -lactam/ β -lactamase inhibitor combinations such as ceftolozane/tazobactam or ceftazidime/avibactam [68,69] have been developed. Data on the efficacy of these antibiotics regarding cIAIs (both administered in combination to metronidazole) are relatively limited and consist of those provided by phase 2 and 3 clinical trials during the registration process [70–72]. Imipenem/relebactam is a β -lactam/new β -lactamase inhibitor antibiotic with a favorable safety and efficacy profile presented in a phase 2/3 study of patients with cIAI [73,74]. This new antibiotic shows a promising profile in the treatment of NP (when *Pseudomonas aeruginosa* may be involved) as part of a combination regimen, at least in the empirical regimen. Eravacycline, a fully synthetic fluorocycline tetracycline antibiotic, has been also shown to be noninferior to carbapenem in adult patients with cIAI in a phase 2 and 3 trial including infections caused by MDR pathogens [75,76]. Most new antibiotics against Gram-negative MDR bacteria are parts of the proposed antibiotic regimens in case of MDR risk factors in severe patients and in ICU settings with endemic or epidemic presence of carbapenem-resistant bacteria [66].

Another strategy for establishing appropriate antibiotic treatment in patients with cIAIs is to consider the presence or absence of risk factors for the presence of MDR bacteria. Patients who have been previously colonized with an MDR pathogen, are of older age, have been previously exposed to antibiotics, have advanced comorbid illnesses, show a poor functional status, have prolonged hospital stay, or have been subjected to invasive

procedures (e.g., central venous catheter, mechanical ventilation, renal replacement therapy, etc.) are considered to be at increased risk of MDR infection [77,78]. Positive predictive value of ESBL and Carbapenem Resistance Enterobacterales (CRE) scores do not exceed 50% [79,80], but NPV is higher than 80%, which could be useful for choosing empirical antibiotic regimens. However, risk stratification for MDR remains challenging.

A recent study by Sartelli et al. proposed antibiotic regimens according to the anatomical extent of the infection, the presumed pathogens, the MDR risk, and the patient's clinical condition [66]. Validation of this stratification in ICU patients with NP merits further evaluation.

Antimicrobial de-escalation (ADE) is an important aspect of Antimicrobial Stewardship Programs (ASP) in severely ill infected patients. Compared to other types of infections, ADE is even more relevant in NP where, frequently, combinations of broad-spectrum antimicrobials are administered due to existing risk factors of MDR pathogens. Once antibiotic susceptibility reports are available, careful medical consideration is needed and efforts should be undertaken by the treating physicians for the empirical regimen to be appropriately adapted and tailored, certainly considering, among others, the patient's overall condition and the absence of other infection sites, either confirmed or suspected. Examples of ADE policy include the followings: antibiotics to be tailored to the susceptibility reports, the drug with the narrowest spectrum should be selected whenever possible, monotherapy for certain infection sites and pathogens is possible, a short-course of antibiotic therapy (5–8 days) could be a possible option for critically ill patients with NP under certain conditions, amongst which is adequate and prompt anatomical source control and appropriate antibiotic treatment [81–86]. Regarding the duration of antibiotic treatment, the STOP-IT study in 2015 proposed short antibiotic courses in certain patient populations [81]. The included patients were not severely ill, the APACHE II score was around 10, and the overall mortality was low (1 %). On the other hand, NP in the ICU critically ill patients often presents with sepsis and septic shock and has much higher associated mortality. Therefore, conclusions from the STOP-IT trial cannot not be automatically extrapolated to more severe disease entities. The more representative DURAPOP study found 7 and 14 days of therapy to be comparable in terms of outcomes [82]. Further research is still needed.

7. Source Control

Source control is the mainstay of the treatment of IAI, and this is also the case in NP [87,88]. Incomplete initial source control increases the mortality rates up to more than 40% [89]. The source control procedure should be rapid, definitive, and timely performed [90]. The basic assumptions for this ideal approach are the early recognition of septic patients and their source of infection and the choice of the appropriate procedure, as well as the prevention of infection recurrence.

When the recognition of sepsis onset and the identification of the infection site is not (or cannot be) performed soon after resuscitation, any potentially effective treatment is proved late [91]. When the selected strategy is not adapted to the patient, the disease, and the expertise of the operator, the clinical management becomes more complex [92]. When source control cannot be definitive, a damage control procedure must be considered [93].

When source control is delayed, complex, or protracted, the survival of the patients with nosocomial IAI significantly worsens [94]. Actually, the control of an infection source can vary widely depending on the cause and the site of the infection: it often implies an interventional approach, surgery, or a non-surgical procedure. Generally, the least invasive, yet maximally effective, option should be preferred. Anyhow, the key principles for an ideal source control procedure include sampling for culture and antibiotic susceptibility testing, drainage of collections, debridement, removal of infected devices, decompression, irrigation, and prevention of further contamination. For selected patients with localized infection and mild clinical signs, interventional radiology using a percutaneous approach is aligned with the main principles of an ideal source control intervention as outlined above (sampling for antibiogram, drainage, and lavage) [95]. More rarely, in strictly selected cases

of postoperative leakage (usually, esophageal, rectal, and biliary), endoscopy can play a complementary role with interventional radiology in terms of drainage, irrigation and, above all, prevention of further contamination by clipping or stenting [96].

However, after administering antimicrobials and resuscitation in cases of sepsis or septic shock, surgery remains the cornerstone of successful treatment of NP [97]. Surgical control of the source of NP includes complete debridement of infected and necrotic tissues, evacuation of infected fluid, irrigation, and bowel resection or suture of perforations to stop continued contamination, as well as diversion with stomas to definitively prevent ongoing infection.

8. Open Abdomen

Open abdomen treatment (OAT) is as an option for emergency surgery patients with severe peritonitis and sepsis or septic shock and is summarized in Table 2 [98]. Critical conditions and emergency surgical interventions associated with severe physiological derangements expose patients at risk to increased intra-abdominal pressure. Fluid redistribution may exacerbate intra-abdominal edema, further increasing the pressure in the abdominal compartment. Proper indications for OAT in severe peritonitis have not yet been defined, and for this reason potential indications for OAT are derived from trauma surgery. Those indications are generally utilized to define the critically ill patients who may benefit from abbreviated laparotomy strategy. Risk factors for intra-abdominal hypertension (IAH) or abdominal compartment syndrome (ACS) requiring OAT after trauma include acidosis with $\text{pH} \leq 7.2$, lactate levels ≥ 5 mmol/L, base deficit (BD) ≥ -6 in patients older than 55 years or ≥ -15 in patients younger than 55 years, core temperature ≤ 34 °C, systolic pressure ≤ 70 mmHg, estimated blood loss ≥ 4 L during the operation and/or transfusion requirement ≥ 10 U of packed red blood cells in the pre- or pre- and intraoperative settings, and severe coagulation disorders (INR/PT > 1.5 times normal, with or without concomitant PTT > 1.5 times normal) [99–104]. Additional risk factors should be considered, such as obesity, pancreatitis, hepatic failure/cirrhosis, positive end-expiratory pressure > 10 cm H₂O, respiratory failure, and acute respiratory distress syndrome (ARDS) [105].

Table 2. Current indications for open abdomen therapy (OAT) in nosocomial peritonitis.

Abbreviated Laparotomy due to Severe Physiological Derangement
Need for a deferred intestinal anastomosis
Planned second look for intestinal ischemia
Persistent source of peritonitis (failure of source control)
Extensive visceral oedema with the concern for development of abdominal compartment syndrome

In severe peritonitis, OAT may represent a valid option for outcome optimization. In fact, severe peritonitis may progress to septic shock when definitive surgical procedures may be contraindicated [98,106]. Whenever the patient clinical conditions are critical, the surgical procedure should be abbreviated even in advanced age [107]. In hypotensive patients requiring high doses of vasopressors or inotropes, intestinal continuity restoration may be deferred [108]. If adequate source control cannot be achieved or in case of visceral edema and/or decreased abdominal wall compliance, primary complete fascia closure should not be attempted because of the high risk of IAH and ACS [109]. In all these conditions, OAT may represent the best solution. However, no definitive data exist regarding the use of OAT in treating severe peritonitis; the ongoing Closed Or Open after Source Control Laparotomy for Severe Complicated Intra-Abdominal Sepsis (COOL) trial will hopefully provide an answer to that question [110]. In the meantime, the use of OAT in severe peritonitis should be utilized with caution.

Entero-atmospheric fistula (EAF) and hostile abdomen are recognized complications of OAT. Several risk factors have been recognized to be directly linked to these complications: delayed abdominal closure, unprotected bowel loops during OAT, large volume fluid

resuscitation volume (>5 L/24 h), and the use of polypropylene mesh directly over the bowel [111–117]. A few studies have been published with the International Register of Open Abdomen (IROA study) data. Some factors historically recognized as increasing the risk of EAF and hostile abdomen could not be confirmed in this project: negative pressure wound management (NPWT), presence of bowel injury and repairs or anastomosis, and presence of intra-abdominal sepsis/abscess [118,119]. Other risk factors were added; the main risk factors for EAF in OAT were found to be OAT duration and the nutritional status of the patients [118]. Intra-abdominal sepsis is a risk factor for longer OAT duration and consequently a higher risk of EAF; it is not a direct causal effect on EAF development. Bowel anastomosis and negative pressure were not associated with an increased EAF risk [118,119]. This was found in all patients in the IROA study, including elderly and obese patients and those who were treated with intra-abdominal fluid instillation [120–122].

Because of increased mortality, length of stay, and hospital costs [123], efforts should be taken to prevent these complications. Early abdominal wall closure, patient nutritional status monitoring and optimal nutrition strategy, bowel coverage with plastic sheets, omentum or skin, avoidance of direct application of a synthetic prosthesis on the bowel, avoidance of direct application of NPWT on the viscera, and burying any intestinal anastomosis deep under bowel loops are the main strategies [124–126]. The Abdominal Compartment Society—WSACS proposed a classification of open abdomen according to the different possible conditions, including the presence of EAF or hostile abdomen [126]. Accurate reporting of the intra-abdominal situation in OAT patients should be performed in each surgical exploration.

Antibiotic decision making in these patients is complex, and decisions should be personalized, based on the clinical evaluation of the patient, persistence of intra-abdominal infection, and presence of ongoing contamination. The mere fact of leaving the abdomen open does not justify obligatory antimicrobial therapy and should be accompanied by continuous investigation to rule out or confirm an infection.

9. Conclusions

NP is a particular subgroup of peritonitis, per definition acquired in a health care setting, and often presents as a complication of abdominal surgery. Outcomes are typically unfavorable, particularly when the patient develops septic shock or diffuse peritonitis is present. The microbiology is different from community-acquired disease and antimicrobial therapy should target a wide range of potential pathogens including the MDR bacteria; the optimal choice is ideally driven by the local ecology and the severity of the patient. Risk factors for MDR involvement are similar to those concerning other healthcare- or ICU-associated infections. Fungal (co)infection poses a particular challenge as diagnosis is often difficult and associated with increased mortality. Source control remains the cornerstone of the management of patients with NP and should be timely and effective. Open abdomen therapy may be indicated in selected patients, but its exact role remains to be determined.

Author Contributions: Conceptualization, J.J.D.W. and K.A.; writing—original draft preparation, J.J.D.W., F.C., L.L., E.M., S.R., I.R.-P., M.T. and K.A.; writing—review and editing, J.J.D.W., F.C., L.L., E.M., S.R., I.R.-P., M.T. and K.A.; visualization, J.J.D.W. and L.L.; supervision, J.J.D.W. All authors have read and agreed to the published version of the manuscript.

Funding: J.J.D.W. is supported by the Flanders Research Foundation (1881020N, Sr Clinical Investigator Grant).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Conflicts of Interest: J.D.W. has consulted for Menarini, MSD, Pfizer, ThermoFisher, and Viatriis (honoraria were paid to his institution). The other authors have nothing to report.

References

1. Tochie, J.N.; Agbor, N.V.; Frank Leonel, T.T.; Mbonda, A.; Aji Abang, D.; Danwang, C. Global epidemiology of acute generalised peritonitis: A protocol for a systematic review and meta-analysis. *BMJ Open* **2020**, *10*, e034326. [\[CrossRef\]](#)
2. Blot, S.; De Waele, J.J.; Vogelaers, D. Essentials for selecting antimicrobial therapy for intra-abdominal infections. *Drugs* **2012**, *72*, e17–e32. [\[CrossRef\]](#) [\[PubMed\]](#)
3. Blot, S.; Antonelli, M.; Arvaniti, K.; Blot, K.; Creagh-Brown, B.; de Lange, D.; De Waele, J.; Deschepper, M.; Dikmen, Y.; Dimopoulos, G.; et al. Epidemiology of intra-abdominal infection and sepsis in critically ill patients: “AbSeS”, a multinational observational cohort study and ESICM Trials Group Project. *Intensive Care Med.* **2019**, *45*, 1703–1717. [\[CrossRef\]](#) [\[PubMed\]](#)
4. Gauzit, R.; Pean, Y.; Barth, X.; Mistretta, F.; Lalaude, O. Epidemiology, management, and prognosis of secondary non-postoperative peritonitis: A French prospective observational multicenter study. *Surg. Infect.* **2009**, *10*, 119–127. [\[CrossRef\]](#) [\[PubMed\]](#)
5. Riche, F.C.; Dray, X.; Laisne, M.J.; Mateo, J.; Raskine, L.; Sanson-Le Pors, M.J.; Payen, D.; Valleur, P.; Cholley, B.P. Factors associated with septic shock and mortality in generalized peritonitis: Comparison between community-acquired and postoperative peritonitis. *Crit. Care* **2009**, *13*, R99. [\[CrossRef\]](#) [\[PubMed\]](#)
6. Bassetti, M.; Eckmann, C.; Giacobbe, D.R.; Sartelli, M.; Montravers, P. Post-operative abdominal infections: Epidemiology, operational definitions, and outcomes. *Intensive Care Med.* **2020**, *46*, 163–172. [\[CrossRef\]](#) [\[PubMed\]](#)
7. Clements, T.W.; Tolonen, M.; Ball, C.G.; Kirkpatrick, A.W. Secondary Peritonitis and Intra-Abdominal Sepsis: An Increasingly Global Disease in Search of Better Systemic Therapies. *Scand. J. Surg.* **2021**, *110*, 139–149. [\[CrossRef\]](#)
8. Ross, J.T.; Matthay, M.A.; Harris, H.W. Secondary peritonitis: Principles of diagnosis and intervention. *BMJ* **2018**, *361*, k1407. [\[CrossRef\]](#)
9. Yeung, D.E.; Peterknecht, E.; Hajibandeh, S.; Hajibandeh, S.; Torrance, A.W. C-reactive protein can predict anastomotic leak in colorectal surgery: A systematic review and meta-analysis. *Int. J. Colorectal Dis.* **2021**, *36*, 1147–1162. [\[CrossRef\]](#)
10. Bona, D.; Danelli, P.; Sozzi, A.; Sanzi, M.; Cayre, L.; Lombardo, F.; Bonitta, G.; Cavalli, M.; Campanelli, G.; Aiolfi, A. C-reactive Protein and Procalcitonin Levels to Predict Anastomotic Leak After Colorectal Surgery: Systematic Review and Meta-analysis. *J. Gastrointest. Surg.* **2023**, *27*, 166–179. [\[CrossRef\]](#)
11. Samji, K.B.; Kielar, A.Z.; Connolly, M.; Fasih, N.; Doherty, G.; Chung, A.; Hache, E. Anastomotic Leaks After Small- and Large-Bowel Surgery: Diagnostic Performance of CT and the Importance of Intraluminal Contrast Administration. *AJR Am. J. Roentgenol.* **2018**, *210*, 1259–1265. [\[CrossRef\]](#) [\[PubMed\]](#)
12. Reitz, K.M.; Kennedy, J.; Li, S.R.; Handzel, R.; Tonetti, D.A.; Neal, M.D.; Zuckerbraun, B.S.; Hall, D.E.; Sperry, J.L.; Angus, D.C.; et al. Association Between Time to Source Control in Sepsis and 90-Day Mortality. *JAMA Surg.* **2022**, *157*, 817–826. [\[CrossRef\]](#) [\[PubMed\]](#)
13. Blot, S.; De Waele, J.J. Critical issues in the clinical management of complicated intra-abdominal infections. *Drugs* **2005**, *65*, 1611–1620. [\[CrossRef\]](#) [\[PubMed\]](#)
14. de Ruiter, J.; Weel, J.; Manusama, E.; Kingma, W.P.; van der Voort, P.H. The epidemiology of intra-abdominal flora in critically ill patients with secondary and tertiary abdominal sepsis. *Infection* **2009**, *37*, 522–527. [\[CrossRef\]](#) [\[PubMed\]](#)
15. Dupont, H.; Montravers, P.; Mohler, J.; Carbon, C. Disparate findings on the role of virulence factors of *Enterococcus faecalis* in mouse and rat models of peritonitis. *Infect. Immun.* **1998**, *66*, 2570–2575. [\[CrossRef\]](#)
16. Fierobe, L.; Decre, D.; Muller, C.; Lucet, J.C.; Marmuse, J.P.; Mantz, J.; Desmonts, J.M. Methicillin-resistant *Staphylococcus aureus* as a causative agent of postoperative intra-abdominal infection: Relation to nasal colonization. *Clin. Infect. Dis.* **1999**, *29*, 1231–1238. [\[CrossRef\]](#)
17. Roehrborn, A.; Thomas, L.; Potreck, O.; Ebener, C.; Ohmann, C.; Goretzki, P.E.; Roher, H.D. The microbiology of postoperative peritonitis. *Clin. Infect. Dis.* **2001**, *33*, 1513–1519. [\[CrossRef\]](#)
18. Montravers, P.; Dupont, H.; Gauzit, R.; Veber, B.; Auboyer, C.; Blin, P.; Hennequin, C.; Martin, C. Candida as a risk factor for mortality in peritonitis. *Crit. Care Med.* **2006**, *34*, 646–652. [\[CrossRef\]](#)
19. Montravers, P.; Lepape, A.; Dubreuil, L.; Gauzit, R.; Pean, Y.; Benchimol, D.; Dupont, H. Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: Results of the French prospective, observational EBIIA study. *J. Antimicrob. Chemother.* **2009**, *63*, 785–794. [\[CrossRef\]](#)
20. De Waele, J.J. What every intensivist should know about the management of peritonitis in the intensive care unit. *Rev. Bras. Ter. Intensiva* **2018**, *30*, 9–14. [\[CrossRef\]](#)
21. De Waele, J.; Lipman, J.; Sakr, Y.; Marshall, J.C.; Vanhems, P.; Barrera Groba, C.; Leone, M.; Vincent, J.L.; EPIC, I.I.I. Abdominal infections in the intensive care unit: Characteristics, treatment and determinants of outcome. *BMC Infect. Dis.* **2014**, *14*, 420. [\[CrossRef\]](#)
22. Fisher, K.; Phillips, C. The ecology, epidemiology and virulence of *Enterococcus*. *Microbiology* **2009**, *155*, 1749–1757. [\[CrossRef\]](#) [\[PubMed\]](#)
23. Dupont, H.; Friggeri, A.; Touzeau, J.; Airapetian, N.; Tinturier, F.; Lobjoie, E.; Lorne, E.; Hijazi, M.; Regimbeau, J.M.; Mahjoub, Y. Enterococci increase the morbidity and mortality associated with severe intra-abdominal infections in elderly patients hospitalized in the intensive care unit. *J. Antimicrob. Chemother.* **2011**, *66*, 2379–2385. [\[CrossRef\]](#) [\[PubMed\]](#)
24. Steinbach, C.L.; Töpfer, C.; Adam, T.; Kees, M.G. Spectrum adequacy of antibiotic regimens for secondary peritonitis: A retrospective analysis in intermediate and intensive care unit patients. *Ann. Clin. Microbiol. Antimicrob.* **2015**, *14*, 48. [\[CrossRef\]](#) [\[PubMed\]](#)

25. Augustin, P.; Kermarrec, N.; Muller-Serieys, C.; Lasocki, S.; Chosidow, D.; Marmuse, J.-P.; Valin, N.; Desmonts, J.-M.; Montravers, P. Risk factors for multidrug resistant bacteria and optimization of empirical antibiotic therapy in postoperative peritonitis. *Crit. Care* **2010**, *14*, R20. [\[CrossRef\]](#)
26. Montravers, P.; Gauzit, R.; Muller, C.; Marmuse, J.P.; Fichelle, A.; Desmonts, J.M. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. *Clin. Infect. Dis.* **1996**, *23*, 486–494. [\[CrossRef\]](#)
27. Seguin, P.; Laviolle, B.; Chanavaz, C.; Donnio, P.Y.; Gautier-Lerestif, A.L.; Campion, J.P.; Malledant, Y. Factors associated with multidrug-resistant bacteria in secondary peritonitis: Impact on antibiotic therapy. *Clin. Microbiol. Infect.* **2006**, *12*, 980–985. [\[CrossRef\]](#)
28. Montravers, P.; Blot, S.; Dimopoulos, G.; Eckmann, C.; Eggimann, P.; Guirao, X.; Paiva, J.A.; Sganga, G.; De Waele, J. Therapeutic management of peritonitis: A comprehensive guide for intensivists. *Intensive Care Med.* **2016**, *42*, 1234–1247. [\[CrossRef\]](#)
29. Karlowsky, J.A.; Hoban, D.J.; Hackel, M.A.; Lob, S.H.; Sahm, D.F. Resistance among Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Latin American countries: SMART 2013–2015. *Braz. J. Infect. Dis.* **2017**, *21*, 343–348. [\[CrossRef\]](#)
30. Chang, Y.T.; Coombs, G.; Ling, T.; Balaji, V.; Rodrigues, C.; Mikamo, H.; Kim, M.J.; Rajasekaram, D.G.; Mendoza, M.; Tan, T.Y.; et al. Epidemiology and trends in the antibiotic susceptibilities of Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region, 2010–2013. *Int. J. Antimicrob. Agents* **2017**, *49*, 734–739. [\[CrossRef\]](#)
31. Bassetti, M.; Righi, E.; Ansaldi, F.; Merelli, M.; Scarparo, C.; Antonelli, M.; Garnacho-Montero, J.; Diaz-Martin, A.; Palacios-Garcia, I.; Luzzati, R.; et al. A multicenter multinational study of abdominal candidiasis: Epidemiology, outcomes and predictors of mortality. *Intensive Care Med.* **2015**, *41*, 1601–1610. [\[CrossRef\]](#) [\[PubMed\]](#)
32. Nadeau-Fredette, A.C.; Bargman, J.M. Characteristics and outcomes of fungal peritonitis in a modern North American cohort. *Perit. Dial. Int.* **2015**, *35*, 78–84. [\[CrossRef\]](#) [\[PubMed\]](#)
33. Bassetti, M.; Vena, A.; Giacobbe, D.R.; Trucchi, C.; Ansaldi, F.; Antonelli, M.; Adamkova, V.; Alicino, C.; Almyroudi, M.P.; Atchade, E.; et al. Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study. *Infect. Dis. Ther.* **2022**, *11*, 827–840. [\[CrossRef\]](#) [\[PubMed\]](#)
34. Lamoth, F.; Lockhart, S.R.; Berkow, E.L.; Calandra, T. Changes in the epidemiological landscape of invasive candidiasis. *J. Antimicrob. Chemother.* **2018**, *73*, i4–i13. [\[CrossRef\]](#)
35. Martin-Loeches, I.; Antonelli, M.; Cuenca-Estrella, M.; Dimopoulos, G.; Einav, S.; De Waele, J.J.; Garnacho-Montero, J.; Kanj, S.S.; Machado, F.R.; Montravers, P.; et al. ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients. *Intensive Care Med.* **2019**, *45*, 789–805. [\[CrossRef\]](#) [\[PubMed\]](#)
36. Lagunes, L.; Rey-Pérez, A. What’s new in intraabdominal candidiasis in critically ill patients, a review. *Hosp. Pract.* **2019**, *47*, 171–176. [\[CrossRef\]](#)
37. Azoulay, E.; Dupont, H.; Tabah, A.; Lortholary, O.; Stahl, J.P.; Francais, A.; Martin, C.; Guidet, B.; Timsit, J.F. Systemic antifungal therapy in critically ill patients without invasive fungal infection. *Crit. Care Med.* **2012**, *40*, 813–822. [\[CrossRef\]](#)
38. Timsit, J.F.; Azoulay, E.; Schwebel, C.; Charles, P.E.; Cornet, M.; Souweine, B.; Klouche, K.; Jaber, S.; Trouillet, J.L.; Bruneel, F.; et al. Empirical Micafungin Treatment and Survival Without Invasive Fungal Infection in Adults With ICU-Acquired Sepsis, Candida Colonization, and Multiple Organ Failure: The EMPIRICUS Randomized Clinical Trial. *JAMA* **2016**, *316*, 1555–1564. [\[CrossRef\]](#)
39. Bailly, S.; Bouadma, L.; Azoulay, E.; Orgeas, M.G.; Adrie, C.; Souweine, B.; Schwebel, C.; Maubon, D.; Hamidfar-Roy, R.; Darmon, M.; et al. Failure of empirical systemic antifungal therapy in mechanically ventilated critically ill patients. *Am. J. Respir. Crit. Care Med.* **2015**, *191*, 1139–1146. [\[CrossRef\]](#)
40. Ostrosky-Zeichner, L.; Shoham, S.; Vazquez, J.; Reboli, A.; Betts, R.; Barron, M.A.; Schuster, M.; Judson, M.A.; Revankar, S.G.; Caeiro, J.P.; et al. MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. *Clin. Infect. Dis.* **2014**, *58*, 1219–1226. [\[CrossRef\]](#)
41. Ullmann, A.J.; Cornely, O.A.; Donnelly, J.P.; Akova, M.; Arendrup, M.C.; Arikan-Akdagli, S.; Bassetti, M.; Bille, J.; Calandra, T.; Castagnola, E.; et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: Developing European guidelines in clinical microbiology and infectious diseases. *Clin. Microbiol. Infect.* **2012**, *18* (Suppl. S7), 1–8. [\[CrossRef\]](#) [\[PubMed\]](#)
42. Pappas, P.G.; Kauffman, C.A.; Andes, D.R.; Clancy, C.J.; Marr, K.A.; Ostrosky-Zeichner, L.; Reboli, A.C.; Schuster, M.G.; Vazquez, J.A.; Walsh, T.J.; et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. *Clin. Infect. Dis.* **2016**, *62*, e1–e50. [\[CrossRef\]](#) [\[PubMed\]](#)
43. Bailly, S.; Leroy, O.; Montravers, P.; Constantin, J.M.; Dupont, H.; Guillemot, D.; Lortholary, O.; Mira, J.P.; Perrigault, P.F.; Gangneux, J.P.; et al. Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: Post hoc analyses of the AmarCAND2 study data. *Intensive Care Med.* **2015**, *41*, 1931–1940. [\[CrossRef\]](#) [\[PubMed\]](#)
44. Lagunes, L.; Rey-Pérez, A.; Martín-Gómez, M.T.; Vena, A.; de Egea, V.; Muñoz, P.; Bouza, E.; Díaz-Martín, A.; Palacios-García, I.; Garnacho-Montero, J.; et al. Association between source control and mortality in 258 patients with intra-abdominal candidiasis: A retrospective multi-centric analysis comparing intensive care versus surgical wards in Spain. *Eur. J. Clin. Microbiol. Infect. Dis.* **2017**, *36*, 95–104. [\[CrossRef\]](#) [\[PubMed\]](#)

45. Solomkin, J.S.; Mazuski, J.E.; Bradley, J.S.; Rodvold, K.A.; Goldstein, E.J.; Baron, E.J.; O'Neill, P.J.; Chow, A.W.; Dellinger, E.P.; Eachempati, S.R.; et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. *Surg. Infect.* **2010**, *11*, 79–109. [\[CrossRef\]](#)
46. Montravers, P.; Dupont, H.; Leone, M.; Constantin, J.M.; Mertes, P.M.; Société française d'anesthésie et de réanimation (Sfar); Société de réanimation de langue française (SRLF); Laterre, P.F.; Misset, B.; Société de pathologie infectieuse de langue française (SPILF); et al. Guidelines for management of intra-abdominal infections. *Anaesth. Crit. Care Pain. Med.* **2015**, *34*, 117–130. [\[CrossRef\]](#)
47. Sartelli, M.; Viale, P.; Catena, F.; Ansaloni, L.; Moore, E.; Malangoni, M.; Moore, F.A.; Velmahos, G.; Coimbra, R.; Ivatury, R.; et al. 2013 WSES guidelines for management of intra-abdominal infections. *World J. Emerg. Surg.* **2013**, *8*, 3. [\[CrossRef\]](#)
48. Guirao, X.; Arias, J.; Badía, J.M.; García-Rodríguez, J.A.; Mensa, J.; Alvarez-Lerma, F.; Borges, M.; Barberán, J.; Maseda, E.; Salavert, M.; et al. Recommendations in the empiric anti-infective agents of intra-abdominal infection. *Rev. Esp. Quimioter* **2009**, *22*, 151–172. [\[CrossRef\]](#)
49. Kurup, A.; Liao, K.H.; Ren, J.; Lu, M.C.; Navarro, N.S.; Farooka, M.W.; Usman, N.; Destura, R.V.; Sirichindakul, B.; Tantawichien, T.; et al. Antibiotic management of complicated intra-abdominal infections in adults: The Asian perspective. *Ann. Med. Surg.* **2014**, *3*, 85–91. [\[CrossRef\]](#)
50. Syue, L.S.; Chen, Y.H.; Ko, W.C.; Hsueh, P.R. New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance. *Int. J. Antimicrob. Agents* **2016**, *47*, 250–258. [\[CrossRef\]](#)
51. Sartelli, M. A focus on intra-abdominal infections. *World J. Emerg. Surg.* **2010**, *5*, 9. [\[CrossRef\]](#) [\[PubMed\]](#)
52. Chong, Y.P.; Bae, I.G.; Lee, S.R.; Chung, J.W.; Jun, J.B.; Choo, E.J.; Moon, S.Y.; Lee, M.S.; Jeon, M.H.; Song, E.H.; et al. Clinical and Economic Consequences of Failure of Initial Antibiotic Therapy for Patients with Community-Onset Complicated Intra-Abdominal Infections. *PLoS ONE* **2015**, *10*, e0119956. [\[CrossRef\]](#) [\[PubMed\]](#)
53. Missing Information on Sample Size. *JAMA* **2019**, *321*, 2370. [\[CrossRef\]](#) [\[PubMed\]](#)
54. Stewart, A.G.; Paterson, D.L.; Young, B.; Lye, D.C.; Davis, J.S.; Schneider, K.; Yilmaz, M.; Dinleyici, R.; Runnegar, N.; Henderson, A.; et al. Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β -Lactamase-Producing *Enterobacter* spp., *Citrobacter freundii*, *Morganella morganii*, *Providencia* spp., or *Serratia marcescens*: A Pilot Multicenter Randomized Controlled Trial (MERINO-2). *Open Forum Infect. Dis.* **2021**, *8*, ofab387. [\[CrossRef\]](#) [\[PubMed\]](#)
55. Hombach, M.; Mouttet, B.; Bloemberg, G.V. Consequences of revised CLSI and EUCAST guidelines for antibiotic susceptibility patterns of ESBL- and AmpC β -lactamase-producing clinical Enterobacteriaceae isolates. *J. Antimicrob. Chemother.* **2013**, *68*, 2092–2098. [\[CrossRef\]](#) [\[PubMed\]](#)
56. Paul, M.; Carrara, E.; Retamar, P.; Tängdén, T.; Bitterman, R.; Bonomo, R.A.; de Waele, J.; Daikos, G.L.; Akova, M.; Harbarth, S.; et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine). *Clin. Microbiol. Infect.* **2022**, *28*, 521–547. [\[CrossRef\]](#) [\[PubMed\]](#)
57. Pitout, J.D. Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: Changing epidemiology and drug treatment choices. *Drugs* **2010**, *70*, 313–333. [\[CrossRef\]](#) [\[PubMed\]](#)
58. Endimiani, A.; Paterson, D.L. Optimizing therapy for infections caused by enterobacteriaceae producing extended-spectrum beta-lactamases. *Semin. Respir. Crit. Care Med.* **2007**, *28*, 646–655. [\[CrossRef\]](#)
59. Cantón, R.; Loza, E.; Aznar, J.; Calvo, J.; Cercenado, E.; Cisterna, R.; Romo, F.G.; Hontangas, J.L.; Calvo, C.R.; Barrenechea, A.I.; et al. Antimicrobial susceptibility of Gram-negative organisms from intraabdominal infections and evolution of isolates with extended spectrum β -lactamases in the SMART study in Spain (2002–2010). *Rev. Esp. Quimioter.* **2011**, *24*, 223–232.
60. Hayajneh, W.A.; Hajj, A.; Hulliel, F.; Sarkis, D.K.; Irani-Hakimeh, N.; Kazan, L.; Badal, R.E. Susceptibility trends and molecular characterization of Gram-negative bacilli associated with urinary tract and intra-abdominal infections in Jordan and Lebanon: SMART 2011–2013. *Int. J. Infect. Dis.* **2015**, *35*, 56–61. [\[CrossRef\]](#)
61. Lee, Y.L.; Chen, Y.S.; Toh, H.S.; Huang, C.C.; Liu, Y.M.; Ho, C.M.; Lu, P.L.; Ko, W.C.; Chen, Y.H.; Wang, J.H.; et al. Antimicrobial susceptibility of pathogens isolated from patients with complicated intra-abdominal infections at five medical centers in Taiwan that continuously participated in the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2006 to 2010. *Int. J. Antimicrob. Agents* **2012**, *40*, S29–S36. [\[CrossRef\]](#) [\[PubMed\]](#)
62. Maseda, E.; Suárez-de-la-Rica, A.; Anillo, V.; Salgado, P.; Tamayo, E.; García-Bernedo, C.A.; Ramasco, F.; Villagrán, M.J.; López-Tofiño, A.; Giménez, M.J.; et al. A practice-based observational study identifying factors associated with the use of high-dose tigecycline in the treatment of secondary peritonitis in severely ill patients. *Rev. Esp. Quimioter.* **2015**, *28*, 47–53.
63. Swenson, B.R.; Metzger, R.; Hedrick, T.L.; McElearney, S.T.; Evans, H.L.; Smith, R.L.; Chong, T.W.; Popovsky, K.A.; Pruett, T.L.; Sawyer, R.G. Choosing antibiotics for intra-abdominal infections: What do we mean by “high risk”? *Surg. Infect.* **2009**, *10*, 29–39. [\[CrossRef\]](#) [\[PubMed\]](#)
64. Maseda, E.; Mensa, J.; Valía, J.C.; Gomez-Herreras, J.I.; Ramasco, F.; Samso, E.; Chiveli, M.A.; Pereira, J.; González, R.; Aguilar, G.; et al. Bugs, hosts and ICU environment: Countering pan-resistance in nosocomial microbiota and treating bacterial infections in the critical care setting. *Rev. Esp. Quimioter.* **2013**, *26*, 312–331. [\[CrossRef\]](#) [\[PubMed\]](#)
65. Arias, C.A.; Murray, B.E. The rise of the Enterococcus: Beyond vancomycin resistance. *Nat. Rev. Microbiol.* **2012**, *10*, 266–278. [\[CrossRef\]](#) [\[PubMed\]](#)

66. Sartelli, M.; Cristini, F.; Coccolini, F.; Labricciosa, F.M.; Siquini, W.; Catena, F. A Proposal for a Classification Guiding the Selection of Appropriate Antibiotic Therapy for Intra-Abdominal Infections. *Antibiotics* **2022**, *11*, 1394. [\[CrossRef\]](#)
67. Morvan, A.C.; Hengy, B.; Garrouste-Orgeas, M.; Ruckly, S.; Forel, J.M.; Argaud, L.; Rimmelé, T.; Bedos, J.P.; Azoulay, E.; Dupuis, C.; et al. Impact of species and antibiotic therapy of enterococcal peritonitis on 30-day mortality in critical care—an analysis of the OUTCOMEREA database. *Crit. Care* **2019**, *23*, 307. [\[CrossRef\]](#)
68. Maseda, E.; Aguilar, L.; Gimenez, M.J.; Gilsanz, F. Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections. *Expert. Rev. Anti Infect. Ther.* **2014**, *12*, 1311–1324. [\[CrossRef\]](#)
69. Liscio, J.L.; Mahoney, M.V.; Hirsch, E.B. Ceftolozane/tazobactam and ceftazidime/avibactam: Two novel β -lactam/ β -lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. *Int. J. Antimicrob. Agents* **2015**, *46*, 266–271. [\[CrossRef\]](#)
70. Solomkin, J.; Hershberger, E.; Miller, B.; Popejoy, M.; Friedland, I.; Steenbergen, J.; Yoon, M.; Collins, S.; Yuan, G.; Barie, P.S.; et al. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-clAI). *Clin. Infect. Dis.* **2015**, *60*, 1462–1471. [\[CrossRef\]](#)
71. Lucasti, C.; Popescu, I.; Ramesh, M.K.; Lipka, J.; Sable, C. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: Results of a randomized, double-blind, Phase II trial. *J. Antimicrob. Chemother.* **2013**, *68*, 1183–1192. [\[CrossRef\]](#)
72. Mazuski, J.E.; Gasink, L.B.; Armstrong, J.; Broadhurst, H.; Stone, G.G.; Rank, D.; Llorens, L.; Newell, P.; Pacht, J. Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infection—Results from a Randomized, Controlled, Double-Blind, Phase 3 Program. *Clin. Infect. Dis.* **2016**, *62*, 1380–1389. [\[CrossRef\]](#) [\[PubMed\]](#)
73. Lucasti, C.; Vasile, L.; Sandesc, D.; Venskutonis, D.; McLeroth, P.; Lala, M.; Rizk, M.L.; Brown, M.L.; Losada, M.C.; Pedley, A.; et al. Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection. *Antimicrob. Agents Chemother.* **2016**, *60*, 6234–6243. [\[CrossRef\]](#) [\[PubMed\]](#)
74. Kohno, S.; Bando, H.; Yoneyama, F.; Kikukawa, H.; Kawahara, K.; Shirakawa, M.; Aoyama, N.; Brown, M.; Paschke, A.; Takase, A. The safety and efficacy of relebactam/imipenem/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: A multicenter, open-label, noncomparative phase 3 study. *J. Infect. Chemother.* **2021**, *27*, 262–270. [\[CrossRef\]](#) [\[PubMed\]](#)
75. Solomkin, J.S.; Gardovskis, J.; Lawrence, K.; Montravers, P.; Sway, A.; Evans, D.; Tsai, L. IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections. *Clin. Infect. Dis.* **2019**, *69*, 921–929. [\[CrossRef\]](#) [\[PubMed\]](#)
76. Solomkin, J.; Evans, D.; Slepavicius, A.; Lee, P.; Marsh, A.; Tsai, L.; Sutcliffe, J.A.; Horn, P. Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial. *JAMA Surg.* **2017**, *152*, 224–232. [\[CrossRef\]](#) [\[PubMed\]](#)
77. Cano, A.; Gutiérrez-Gutiérrez, B.; Machuca, I.; Gracia-Ahufinger, I.; Pérez-Nadales, E.; Causse, M.; Castón, J.J.; Guzmán-Puche, J.; Torre-Giménez, J.; Kindelán, L.; et al. Risks of Infection and Mortality Among Patients Colonized with *Klebsiella pneumoniae* Carbapenemase-Producing *K. pneumoniae*: Validation of Scores and Proposal for Management. *Clin. Infect. Dis.* **2018**, *66*, 1204–1210. [\[CrossRef\]](#)
78. Giannella, M.; Trecarichi, E.M.; De Rosa, F.G.; Del Bono, V.; Bassetti, M.; Lewis, R.E.; Losito, A.R.; Corcione, S.; Saffioti, C.; Bartoletti, M.; et al. Risk factors for carbapenem-resistant *Klebsiella pneumoniae* bloodstream infection among rectal carriers: A prospective observational multicentre study. *Clin. Microbiol. Infect.* **2014**, *20*, 1357–1362. [\[CrossRef\]](#)
79. Detsis, M.; Karanika, S.; Mylonakis, E. ICU Acquisition Rate, Risk Factors, and Clinical Significance of Digestive Tract Colonization with Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae: A Systematic Review and Meta-Analysis. *Crit. Care Med.* **2017**, *45*, 705–714. [\[CrossRef\]](#)
80. Raman, G.; Avendano, E.E.; Chan, J.; Merchant, S.; Puzniak, L. Risk factors for hospitalized patients with resistant or multidrug-resistant *Pseudomonas aeruginosa* infections: A systematic review and meta-analysis. *Antimicrob. Resist. Infect. Control* **2018**, *7*, 79. [\[CrossRef\]](#)
81. Sawyer, R.G.; Claridge, J.A.; Nathens, A.B.; Rotstein, O.D.; Duane, T.M.; Evans, H.L.; Cook, C.H.; O'Neill, P.J.; Mazuski, J.E.; Askari, R.; et al. Trial of short-course antimicrobial therapy for intraabdominal infection. *N. Engl. J. Med.* **2015**, *372*, 1996–2005. [\[CrossRef\]](#) [\[PubMed\]](#)
82. Montravers, P.; Tubach, F.; Lescot, T.; Veber, B.; Esposito-Farèse, M.; Seguin, P.; Paugam, C.; Lepape, A.; Meistelman, C.; Cousson, J.; et al. Short-course antibiotic therapy for critically ill patients treated for postoperative intra-abdominal infection: The DURAPOP randomised clinical trial. *Intensive Care Med.* **2018**, *44*, 300–310. [\[CrossRef\]](#) [\[PubMed\]](#)
83. Suarez-de-la-Rica, A.; Gilsanz, F.; Maseda, E.; Montravers, P.; Lasocki, S.; Lescot, T.; Dupont, H. Is very short-course antibiotic therapy possible in postoperative intra-abdominal infections? Discussion on “Short-course antibiotic therapy for critically ill patients treated for postoperative intra-abdominal infection: The DURAPOP randomised clinical trial”. *Intensive Care Med.* **2018**, *44*, 695–696. [\[CrossRef\]](#) [\[PubMed\]](#)
84. Maseda, E.; Suarez-de-la-Rica, A.; Anillo, V.; Tamayo, E.; Garcia-Bernedo, C.A.; Ramasco, F.; Villagran, M.J.; Maggi, G.; Gimenez, M.J.; Aguilar, L.; et al. Procalcitonin-guided therapy may reduce length of antibiotic treatment in intensive care unit patients with secondary peritonitis: A multicenter retrospective study. *J. Crit. Care* **2014**, *30*, 537–542. [\[CrossRef\]](#) [\[PubMed\]](#)

85. Montravers, P.; Augustin, P.; Grall, N.; Desmard, M.; Allou, N.; Marmuse, J.P.; Guglielminotti, J. Characteristics and outcomes of anti-infective de-escalation during health care-associated intra-abdominal infections. *Crit. Care* **2016**, *20*, 83. [\[CrossRef\]](#)
86. Tabah, A.; Cotta, M.O.; Garnacho-Montero, J.; Schouten, J.; Roberts, J.A.; Lipman, J.; Tacey, M.; Timsit, J.F.; Leone, M.; Zahar, J.R.; et al. A Systematic Review of the Definitions, Determinants, and Clinical Outcomes of Antimicrobial De-escalation in the Intensive Care Unit. *Clin. Infect. Dis.* **2016**, *62*, 1009–1017. [\[CrossRef\]](#)
87. De Waele, J.J.; Girardis, M.; Martin-Loeches, I. Source control in the management of sepsis and septic shock. *Intensive Care Med.* **2022**, *48*, 1799–1802. [\[CrossRef\]](#)
88. Evans, L.; Rhodes, A.; Alhazzani, W.; Antonelli, M.; Coopersmith, C.M.; French, C.; Machado, F.R.; McIntyre, L.; Ostermann, M.; Prescott, H.C.; et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. *Crit Care Med* **2021**, *49*, e1063–e1143. [\[CrossRef\]](#)
89. Hecker, A.; Reichert, M.; Reuß, C.J.; Schmoch, T.; Riedel, J.G.; Schneck, E.; Padberg, W.; Weigand, M.A.; Hecker, M. Intra-abdominal sepsis: New definitions and current clinical standards. *Langenbecks Arch. Surg.* **2019**, *404*, 257–271. [\[CrossRef\]](#)
90. De Waele, J.J. Early source control in sepsis. *Langenbecks Arch. Surg.* **2010**, *395*, 489–494. [\[CrossRef\]](#)
91. Azuhata, T.; Kinoshita, K.; Kawano, D.; Komatsu, T.; Sakurai, A.; Chiba, Y.; Tanjho, K. Time from admission to initiation of surgery for source control is a critical determinant of survival in patients with gastrointestinal perforation with associated septic shock. *Crit. Care* **2014**, *18*, R87. [\[CrossRef\]](#) [\[PubMed\]](#)
92. Bloos, F.; Rüdell, H.; Thomas-Rüdell, D.; Schwarzkopf, D.; Pausch, C.; Harbarth, S.; Schreiber, T.; Gründling, M.; Marshall, J.; Simon, P.; et al. Effect of a multifaceted educational intervention for anti-infectious measures on sepsis mortality: A cluster randomized trial. *Intensive Care Med.* **2017**, *43*, 1602–1612. [\[CrossRef\]](#) [\[PubMed\]](#)
93. Kwon, E.; Krause, C.; Luo-Owen, X.; McArthur, K.; Cochran-Yu, M.; Swentek, L.; Burruss, S.; Turay, D.; Krasnoff, C.; Grigorian, A.; et al. Time is domain: Factors affecting primary fascial closure after trauma and non-trauma damage control laparotomy (data from the EAST SLEEP-TIME multicenter registry). *Eur. J. Trauma. Emerg. Surg.* **2022**, *48*, 2107–2116. [\[CrossRef\]](#) [\[PubMed\]](#)
94. De Pascale, G.; Antonelli, M.; Deschepper, M.; Arvaniti, K.; Blot, K.; Brown, B.C.; de Lange, D.; De Waele, J.; Dikmen, Y.; Dimopoulos, G.; et al. Poor timing and failure of source control are risk factors for mortality in critically ill patients with secondary peritonitis. *Intensive Care Med.* **2022**, *48*, 1593–1606. [\[CrossRef\]](#)
95. Soop, M.; Carlson, G.L. Recent developments in the surgical management of complex intra-abdominal infection. *Br. J. Surg.* **2017**, *104*, e65–e74. [\[CrossRef\]](#) [\[PubMed\]](#)
96. Cereatti, F.; Grassia, R.; Drago, A.; Conti, C.B.; Donatelli, G. Endoscopic management of gastrointestinal leaks and fistulae: What option do we have. *World J. Gastroenterol.* **2020**, *26*, 4198–4217. [\[CrossRef\]](#) [\[PubMed\]](#)
97. Sartelli, M.; Coccolini, F.; Kluger, Y.; Agastra, E.; Abu-Zidan, F.M.; Abbas, A.E.S.; Ansaloni, L.; Adesunkanmi, A.K.; Atanasov, B.; Augustin, G.; et al. WSES/GAIS/SIS-E/WSIS/AAST global clinical pathways for patients with intra-abdominal infections. *World J. Emerg. Surg.* **2021**, *16*, 49. [\[CrossRef\]](#) [\[PubMed\]](#)
98. Coccolini, F.; Montori, G.; Ceresoli, M.; Catena, F.; Moore, E.E.; Ivatury, R.; Biffl, W.; Peitzman, A.; Coimbra, R.; Rizoli, S.; et al. The role of open abdomen in non-trauma patient: WSES Consensus Paper. *World J. Emerg. Surg.* **2017**, *12*, 39. [\[CrossRef\]](#)
99. Regner, J.L.; Kobayashi, L.; Coimbra, R. Surgical Strategies for Management of the Open Abdomen. *World J. Surg.* **2011**, *36*, 497–510. [\[CrossRef\]](#)
100. Chiara, O.; Cimbani, S.; Biffl, W.; Leppaniemi, A.; Henry, S.; Scalea, T.M.; Catena, F.; Ansaloni, L.; Chiericato, A.; de Blasio, E.; et al. International consensus conference on open abdomen in trauma. *J. Trauma. Acute Care Surg.* **2016**, *80*, 173–183. [\[CrossRef\]](#)
101. Girard, E.; Abba, J.; Boussat, B.; Trilling, B.; Mancini, A.; Bouzat, P.; Létoublon, C.; Chirica, M.; Arvieux, C. Damage Control Surgery for Non-traumatic Abdominal Emergencies. *World J. Surg.* **2017**, *42*, 965–973. [\[CrossRef\]](#) [\[PubMed\]](#)
102. Roberts, D.J.; Bobrovitz, N.; Zygun, D.A.; Ball, C.G.; Kirkpatrick, A.W.; Faris, P.D.; Brohi, K.; D'Amours, S.; Fabian, T.C.; Inaba, K.; et al. Indications for Use of Damage Control Surgery in Civilian Trauma Patients: A Content Analysis and Expert Appropriateness Rating Study. *Ann. Surg.* **2015**, *263*, 1018–1027. [\[CrossRef\]](#) [\[PubMed\]](#)
103. Roberts, D.J.; Bobrovitz, N.; Zygun, D.A.; Ball, C.G.; Kirkpatrick, A.W.; Faris, P.D.; Stelfox, H.T. Indications for use of damage control surgery and damage control interventions in civilian trauma patients: A scoping review. *J. Trauma. Acute Care Surg.* **2015**, *78*, 1187–1196. [\[CrossRef\]](#) [\[PubMed\]](#)
104. Roberts, D.J.; Zygun, D.A.; Faris, P.D.; Ball, C.G.; Kirkpatrick, A.W.; Stelfox, H.T.; Indications for Trauma Damage Control Surgery International Study Group. Opinions of Practicing Surgeons on the Appropriateness of Published Indications for Use of Damage Control Surgery in Trauma Patients: An International Cross-Sectional Survey. *J. Am. Coll. Surg.* **2016**, *223*, 515–529. [\[CrossRef\]](#)
105. Holodinsky, J.K.; Roberts, D.J.; Ball, C.G.; Reintam Blaser, A.; Starkopf, J.; Zygun, D.A.; Stelfox, H.T.; Malbrain, M.L.; Jaeschke, R.C.; Kirkpatrick, A.W. Risk factors for intra-abdominal hypertension and abdominal compartment syndrome among adult intensive care unit patients: A systematic review and meta-analysis. *Crit. Care* **2013**, *17*, R249. [\[CrossRef\]](#)
106. Moore, L.J.; Moore, F.A. Epidemiology of sepsis in surgical patients. *Surg. Clin. N. Am.* **2012**, *92*, 1425–1443. [\[CrossRef\]](#)
107. Weber, D.G.; Bendinelli, C.; Balogh, Z.J. Damage control surgery for abdominal emergencies. *Br. J. Surg.* **2014**, *101*, e109–e118. [\[CrossRef\]](#)
108. Ordóñez, C.A.; Sánchez, A.I.; Pineda, J.A.; Badiel, M.; Mesa, R.; Cardona, U.; Arias, R.; Rosso, F.; Granados, M.; Gutiérrez-Martínez, M.I.; et al. Deferred primary anastomosis versus diversion in patients with severe secondary peritonitis managed with staged laparotomies. *World J. Surg.* **2010**, *34*, 169–176. [\[CrossRef\]](#)

109. Plantefeve, G.; Hellmann, R.; Pajot, O.; Thirion, M.; Bleichner, G.; Mentec, H. Abdominal compartment syndrome and intraabdominal sepsis: Two of the same kind? *Acta Clin. Belg. Suppl.* **2007**, *62*, 162–167. [[CrossRef](#)]
110. Kirkpatrick, A.W.; Coccolini, F.; Ansaloni, L.; Roberts, D.J.; Tolonen, M.; McKee, J.L.; Leppaniemi, A.; Faris, P.; Doig, C.J.; Catena, F.; et al. Closed or Open after Source Control Laparotomy for Severe Complicated Intra-Abdominal Sepsis (the COOL trial): Study protocol for a randomized controlled trial. *World J. Emerg. Surg.* **2018**, *13*, 26. [[CrossRef](#)]
111. Atema, J.J.; Gans, S.L.; Boermeester, M.A. Systematic review and meta-analysis of the open abdomen and temporary abdominal closure techniques in non-trauma patients. *World J. Surg.* **2015**, *39*, 912–925. [[CrossRef](#)] [[PubMed](#)]
112. Richter, S.; Dold, S.; Doberauer, J.P.; Mai, P.; Schuld, J. Negative pressure wound therapy for the treatment of the open abdomen and incidence of enteral fistulas: A retrospective bicentre analysis. *Gastroenterol. Res. Pract.* **2013**, *2013*, 730829. [[CrossRef](#)] [[PubMed](#)]
113. Bradley, M.J.; Dubose, J.J.; Scalea, T.M.; Holcomb, J.B.; Shrestha, B.; Okoye, O.; Inaba, K.; Bee, T.K.; Fabian, T.C.; Whelan, J.F.; et al. Independent predictors of enteric fistula and abdominal sepsis after damage control laparotomy: Results from the prospective AAST Open Abdomen registry. *JAMA Surg.* **2013**, *148*, 947–954. [[CrossRef](#)] [[PubMed](#)]
114. Martinez, J.L.; Luque-de-Leon, E.; Mier, J.; Blanco-Benavides, R.; Robledo, F. Systematic management of postoperative enterocutaneous fistulas: Factors related to outcomes. *World J. Surg.* **2008**, *32*, 436–443; discussion 444. [[CrossRef](#)] [[PubMed](#)]
115. Tavusbay, C.; Genc, H.; Cin, N.; Kar, H.; Kamer, E.; Atahan, K.; Hacıyanlı, M. Use of a vacuum-assisted closure system for the management of enteroatmospheric fistulae. *Surg. Today* **2014**, *45*, 1102–1111. [[CrossRef](#)]
116. D'Hondt, M.; Devriendt, D.; Van Rooy, F.; Vansteenkiste, F.; D'Hoore, A.; Penninckx, F.; Miserez, M. Treatment of small-bowel fistulae in the open abdomen with topical negative-pressure therapy. *Am. J. Surg.* **2011**, *202*, e20–e24. [[CrossRef](#)]
117. Marinis, A.; Gkiokas, G.; Argyra, E.; Fragulidis, G.; Polymeneas, G.; Voros, D. “Enteroatmospheric Fistulae”—Gastrointestinal Openings in the Open Abdomen: A Review and Recent Proposal of a Surgical Technique. *Scand. J. Surg.* **2013**, *102*, 61–68. [[CrossRef](#)]
118. Coccolini, F.; Ceresoli, M.; Kluger, Y.; Kirkpatrick, A.; Montori, G.; Salvetti, F.; Fugazzola, P.; Tomasoni, M.; Sartelli, M.; Ansaloni, L.; et al. Open abdomen and entero-atmospheric fistulae: An interim analysis from the International Register of Open Abdomen (IROA). *Injury* **2019**, *50*, 160–166. [[CrossRef](#)]
119. Coccolini, F.; Montori, G.; Ceresoli, M.; Catena, F.; Ivatury, R.; Sugrue, M.; Sartelli, M.; Fugazzola, P.; Corbella, D.; Salvetti, F.; et al. IROA: International Register of Open Abdomen, preliminary results. *World J. Emerg. Surg.* **2017**, *12*, 10. [[CrossRef](#)]
120. Ceresoli, M.; Salvetti, F.; Kluger, Y.; Braga, M.; Viganò, J.; Fugazzola, P.; Sartelli, M.; Ansaloni, L.; Catena, F.; Coccolini, F.; et al. Open Abdomen in Obese Patients: Pay Attention! New Evidences from IROA, the International Register of Open Abdomen. *World J. Surg.* **2020**, *44*, 53–62. [[CrossRef](#)]
121. Coccolini, F.; Perrina, D.; Ceresoli, M.; Kluger, Y.; Kirkpatrick, A.; Sartelli, M.; Ansaloni, L.; Catena, F. Open abdomen and age: results from IROA (International Register of Open Abdomen). *Am. J. Surg.* **2020**, *220*, 229–236. [[CrossRef](#)] [[PubMed](#)]
122. Coccolini, F.; Gubbiotti, F.; Ceresoli, M.; Tartaglia, D.; Fugazzola, P.; Ansaloni, L.; Sartelli, M.; Kluger, Y.; Kirkpatrick, A.; Amico, F.; et al. Open Abdomen and Fluid Instillation in the Septic Abdomen: Results from the IROA Study. *World J. Surg.* **2020**, *44*, 4032–4040. [[CrossRef](#)] [[PubMed](#)]
123. Teixeira, P.G.; Inaba, K.; Dubose, J.; Salim, A.; Brown, C.; Rhee, P.; Browder, T.; Demetriades, D. Enterocutaneous fistula complicating trauma laparotomy: A major resource burden. *Am. Surg.* **2009**, *75*, 30–32. [[CrossRef](#)] [[PubMed](#)]
124. Schecter, W.P.; Ivatury, R.R.; Rotondo, M.F.; Hirshberg, A. Open abdomen after trauma and abdominal sepsis: A strategy for management. *J. Am. Coll. Surg.* **2006**, *203*, 390–396. [[CrossRef](#)]
125. Carlson, G.L.; Patrick, H.; Amin, A.I.; McPherson, G.; MacLennan, G.; Afolabi, E.; Mowatt, G.; Campbell, B. Management of the Open Abdomen: A National Study of Clinical Outcome and Safety of Negative Pressure Wound Therapy. *Ann. Surg.* **2013**, *257*, 1154–1159. [[CrossRef](#)]
126. Cheatham, M.L.; Demetriades, D.; Fabian, T.C.; Kaplan, M.J.; Miles, W.S.; Schreiber, M.A.; Holcomb, J.B.; Bochicchio, G.; Sarani, B.; Rotondo, M.F. Prospective study examining clinical outcomes associated with a negative pressure wound therapy system and Barker's vacuum packing technique. *World J. Surg.* **2013**, *37*, 2018–2030. [[CrossRef](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.